2023/03/29 by Hartwig, Andrea, MAK Commission
#6-(((4-Methylphenyl)sulfonyl)amino)hexanoic acid #6-(((4-methylphenyl)sulphonyl)amino)hexanoic acid #6-[(4-Methylphenyl)sulfonylamino]hexanoic acid #6-[(4-Methylphenyl)sulfonylamino]hexansäure #6-{[(4-Methylphenyl)sulfonyl]amino}hexansäure #Entwicklungstoxizität #Komplexbildner #Luft #N-Tosyl-6-aminocaproic acid #N-Tosyl-6-aminocapronsäure #Tosylaminohexansäure #Toxizität #air #complexing agent #developmental toxicity #p-Toluolsulfonyl-ε-aminocapronsäure #toxicity
paper · doi:10.34865/mb7852139kskd8_1or
The German Commission for the Investigation of Health Hazards of Chemical Compounds in the Work Area has evaluated N-tosyl-6-aminocaproic acid (6-[(4-methylphenyl)sulfonylamino]hexanoic acid) [78521-39-8] considering all toxicological end points. The substance is a complexing agent. As the influence of the complexing effect and the acid effect on the respiratory tract is not known and inhalation studies are not available, a maximum concentration at the workplace (MAK value) cannot be derived. The NOAEL for developmental effects in rats after oral administration was 100 mg/kg body weight and day. In a gavage study in rats that was carried out according to OECD Test Guideline 422, pup mortality was increased and pup body weights were decreased up to postnatal day 4 at 1600 mg/kg body weight and day. The substance is not genotoxic in bacteria or mammalian cells. Carcinogenicity studies are not available. There is no evidence of a contact sensitizing potential. Skin contact is not expected to contribute significantly to systemic toxicity.